Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Tempus AI Inc (TEM) Is Building the OS for Personalized Medicine— 5 Key Catalysts Driving Platform Monetization!
Tempus AI’s Q1 2025 results underscore its accelerating business model inflection, driven by 75% YoY revenue growth to $255.7M and clear signs of operating leverage, including 610bps gross margin expansion and a $27.8M YoY improvement in adjusted EBITDA losses. Genomics revenue rose 89% YoY, with robust hereditary testing (+23% volume growth) and higher ASPs from xT migration, while the Data & Services segment grew 43% on strong biopharma demand and 58% YoY expansion in the Insights unit. Critically, the $200M foundational model partnership with AstraZeneca and Pathos validates Tempus’ differentiated AI and multimodal data capabilities, and sets the stage for multi-year data monetization beyond one-off licensing. Crossing the $1B mark in remaining contract value enhances revenue visibility, addressing macro concerns around biotech R&D spend. The full-year guidance raise to $1.25B (80% YoY growth) balances early overdelivery with conservative assumptions around nascent AI revenue and reimbursement timing. We see durable genomics momentum, foundational model scalability, and FDA test adoption as structural tailwinds, with upside from MRD reimbursement (xM) and further foundational partnerships. As Tempus positions itself as the OS layer for personalized medicine, can it sustain both topline momentum and gross margin expansion while scaling platform AI delivery into a profitability inflection by FY26?
